Search

Displaying results 8361 - 8370 of 10000 in total
  1. Drug

    Dimethylcurcumin

    go.drugbank.com/drugs/DB06133
    Investigational

    Dimethylcurcumin is a synthetic chemical compound that is loosely based on a compound found in curcumin. It is a novel anti-androgen that enhances androgen receptor degradation.

  2. Drug

    Mianserin

    go.drugbank.com/drugs/DB06148
    ApprovedWithdrawn

    A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of [mirtazapine].

    Synonyms: 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine
  3. Drug

    Garenoxacin

    go.drugbank.com/drugs/DB06160
    Experimental

    Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.

  4. Drug

    Paclitaxel trevatide

    go.drugbank.com/drugs/DB06171
    Investigational

    Three paclitaxel molecules linked by a cleavable succinyl ester linkage to a brain peptide vector, Angiopep-2, conjugate named ANG1005.

    Synonyms: [a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr
  5. Drug

    Solabegron

    go.drugbank.com/drugs/DB06190
    Investigational

    Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.

  6. Drug

    Elocalcitol

    go.drugbank.com/drugs/DB06194
    Experimental

    Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).

  7. Drug

    Exisulind

    go.drugbank.com/drugs/DB06246
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    [L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385]. … Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.

  9. Drug

    Senicapoc

    go.drugbank.com/drugs/DB06280
    Investigational

    Senicapoc (ICA-17043) is a novel Gardos channel blocker.[A259068] It is being investigated for the treatment of sickle cell disease.

  10. Drug

    Sonepcizumab

    go.drugbank.com/drugs/DB06305
    Investigational

    A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities.